The ability to generate new brain cells throughout life could determine whether we maintain sharp cognition or succumb to dementia. This question has profound implications for understanding why some octogenarians retain the memory of someone decades younger while others develop Alzheimer's disease.
Researchers analyzed over 355,000 brain cell nuclei from post-mortem hippocampi across five distinct groups: young adults, cognitively normal elderly, SuperAgers with exceptional memory, those with preclinical Alzheimer's pathology, and Alzheimer's patients. The study confirmed that humans continue producing new neurons in the hippocampus throughout life, but revealed striking differences between groups. SuperAgers displayed a unique neurogenesis signature that distinguished them from typical aging patterns, while individuals with preclinical Alzheimer's showed early disruptions in chromatin accessibility—the molecular machinery that controls gene expression in neurogenic cells.
This represents the most comprehensive molecular mapping of adult human neurogenesis to date, settling decades of scientific debate about whether new neurons form in adult human brains. The chromatin accessibility findings are particularly significant because they suggest neurogenesis dysfunction begins before clinical symptoms appear, potentially offering early intervention targets. The SuperAger resilience signature could illuminate protective mechanisms that maintain cognitive reserve. However, the cross-sectional design cannot establish whether altered neurogenesis causes cognitive decline or results from it. The findings demand longitudinal studies tracking neurogenesis changes over time and investigation of whether interventions targeting chromatin accessibility could preserve or restore neurogenic capacity in aging populations.